anonymous
Guest
anonymous
Guest
From STAT on Dec 19
“Pfizer is this year’s anti-Eli Lilly. If David Ricks is the best biopharma CEO of 2023, then Pfizer CEO Albert Bourla is, unfortunately, the worst.
My annual Worst Biopharma CEO list is typically populated with blockheads and scoundrels. That’s not why Bourla is here. The reason is accountability. Strategic missteps, financial miscalculations, and scientific setbacks have plunged Pfizer into a deep crisis. Bourla is the man at the top, so the responsibility lies with him.”
Finally AB earns an appropriate spot on a bio pharma list. Unfortunately it is a “worst of” list and is a completely earned position. Hope the board takes some time to reflect on a 50% loss of value, stock at a decade low and their CEO recognized as the worst in bio pharma.
Opa!!
WSJ knows, too. They published an article that Pfizer needs to right the ship. The article lists failures, missed opportunities and leadership miscues. The Journal knows, investors know. Just our leadership and board in denial, preparing to dispense rich rewards to the sorry crew